^
Association details:
| Biomarker: | MYC expression + MCL1 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + BR101801 (PI3Kδ inhibitor, PI3Kγ inhibitor, DNA PK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting
Published date:
02/15/2023
Excerpt:
Consistent with these in vitro results, BR101801 also suppressed tumor growth, with a reduction in both Mcl-1 and c-Myc levels in DLBCL xenograft tumors. Therefore, BR101801 could also enhance the antitumor effect of Venetoclax synergistically.....This anti-cancer effect of BR101801 was confirmed in animal models, where it effectively inhibited tumor growth by reducing the expression of both c-Myc and Mcl-1. Furthermore, BR101801 exhibited a significant synergistic antitumor effect even in late xenograft models when combined with Venetoclax.
